Loading…
Loading…
GTHP does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GTHP and 80,000+ other tickers.
See exactly how GTHP's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GTHP and 80,000+ other tickers.
Guided Therapeutics, Inc. is a medical technology firm specializing in the creation of medical devices. Its primary focus is on bringing to market LuViva, an innovative device designed for the non-invasive detection of cervical cancer. This technology excels at identifying both cancerous and precancerous conditions of the cervix in a painless, non-invasive manner, directly at the point of care. LuViva operates by scanning the cervix with light and subsequently analyzing both the reflected and fluorescent light emitted. Established in 1992 and headquartered in Norcross, Georgia, the company was formerly known as SpectRx, Inc. until its rebranding to Guided Therapeutics, Inc. in February 2008.
Guided Therapeutics, Inc. (OTC: QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a payment of $80,000 from distrib
PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a payment of $80,000 from distribution partner Hangzhou Dongye Medical Technology Company Ltd (HDMT). The payment is the fourth installment of a $700,000 purchase order the Company received from HDMT last year. The four LuViva devices are expected to ship later this year, which will bring the total number of devices shipped to ele.
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection ba
PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today it had filed the results of its multicenter clinical trial with the U.S. Food and Drug Administration (FDA). The study protocol was developed through interactions with FDA and enrolled 480 women referred to biopsy because of abnormal Pap a.
Haemonetics (NYSE: HAE - Get Free Report) and Guided Therapeutics (OTCMKTS:GTHP - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability. Risk and Volatility Haemonetics has a beta of 0.36,